Dr. Vipul Rohidas Wayal is a dynamic postdoctoral researcher specializing in biotechnology, translational medicine, and pharmaceutical sciences. Currently affiliated with Tunghai University in Taiwan, he has demonstrated exceptional expertise in bioactive peptides, metabolic diseases, and immunomodulation. His research has led to several high-impact publications and internationally recognized patents, reflecting strong innovation and translational potential. With a solid academic foundation—holding a Ph.D. in Animal Science and Biotechnology and a Master’s in Pharmaceutics—Dr. Wayal brings interdisciplinary proficiency across advanced bioinformatics, molecular docking, and animal modeling. He has actively contributed to projects targeting MAFLD, T2DM, and atherosclerosis and participated in global scientific forums such as BIO Asia and the Taiwan Innotech Expo. Recognized with scholarships and innovation awards, he is also skilled in scientific writing, grant proposals, and technology transfer. Dr. Wayal’s research impact and forward-thinking approach position him as a promising candidate for honors recognizing excellence in scientific research and innovation.
Google Scholar
Scopus Profile
ORCID Profile
Dr. Vipul Rohidas Wayal has a robust academic background, reflecting a consistent focus on biomedical research and pharmaceutical sciences. He earned his Ph.D. in Animal Science and Biotechnology from Tunghai University, Taiwan, where his thesis explored the ameliorative effects of bioactive oligopeptides on metabolic-associated fatty liver disease (MAFLD) in murine models. His doctoral work integrated molecular biology, pharmacology, and biotechnology. Prior to this, he completed a Master of Pharmacy (M.Pharm) in Pharmaceutics from Rajiv Gandhi University of Health Sciences, Bangalore, India. His master’s thesis focused on the development of silk protein-based topical sprays for wound healing. Dr. Wayal also holds a Bachelor of Pharmacy from Savitribai Phule Pune University, India, where he conducted research on herbal gel formulations for wound healing. Throughout his education, he has cultivated expertise in drug delivery, biotechnology, and disease modeling, laying a solid foundation for translational research and pharmaceutical innovation.
Dr. Wayal brings diverse professional experience, combining academic research with industrial roles. He currently serves as a postdoctoral researcher at Tunghai University, Taiwan, where he is involved in projects focusing on novel fermented foods, immunomodulators, and bioactive peptides for metabolic disorders such as NAFLD and T2DM. His earlier academic experience includes extensive work in molecular biology techniques, animal experimentation, and peptide-based therapeutic research. Before transitioning fully into academia, he held several positions in the pharmaceutical industry in India, including Factory Manager at Equine Nutrients and R&D Production Manager at Fibroheal Woundcare Pvt. Ltd., where he was involved in the development and manufacturing of wound-care products. Additionally, he worked as a Manufacturing Officer at Fresenius Kabi, handling large-scale pharmaceutical production. These roles have equipped him with hands-on expertise in technology transfer, quality control, and product development, giving him a practical perspective that complements his research endeavors.
Dr. Vipul Wayal’s research interests lie at the intersection of biotechnology, pharmaceutical sciences, and translational medicine. He is particularly focused on the discovery and functional evaluation of bioactive peptides and proteins for the prevention and treatment of metabolic diseases such as MAFLD, type 2 diabetes, and atherosclerosis. His work integrates molecular docking, bioinformatics, in vivo modeling, and immunological assays to uncover therapeutic pathways and mechanisms, particularly involving Nrf2/HO-1, TLR4/NF-κB, and inflammasome signaling. Additionally, he is involved in the development of functional foods with cardiovascular and immunomodulatory benefits. His broad skill set includes protein purification, ELISA, flow cytometry, and various forms of chromatography and spectroscopy, which support his bench-to-bedside research approach. Dr. Wayal also emphasizes innovative drug delivery systems, especially in peptide-based therapeutics, and is passionate about bridging the gap between laboratory discoveries and clinical applications through patentable, scalable solutions.
Dr. Vipul Wayal has received recognition for both his academic performance and innovative research contributions. He was awarded the Tunghai University International Student Scholarship consecutively for the academic years 2021–2022 and 2022–2023, acknowledging his academic excellence and research productivity during his doctoral studies. One of his most notable achievements includes receiving the Excellent Idea Certificate for his patented innovation on “Novel Small Molecule Peptides for Anti-MAFLD Activity,” which has been granted in Taiwan and Japan and filed in the United States. His participation in international expos and conferences, such as the Taiwan Innotech Expo and BIO Asia–Taiwan, further emphasizes his growing international profile. These honors reflect his commitment to advancing science through novel and applicable innovations. While his accolades are notable, they also signal his potential for future recognition as his research continues to expand and influence both academic and applied biomedical fields.
In conclusion, Dr. Vipul Rohidas Wayal exemplifies a rising biomedical scientist with an impressive combination of academic excellence, industrial experience, and innovative research. His work in bioactive peptides, metabolic disease therapeutics, and functional food development has resulted in impactful publications and internationally recognized patents. He possesses a wide range of technical skills, from molecular biology to in silico modeling, supported by a solid educational foundation and cross-disciplinary collaborations. With experience spanning academia and pharmaceutical industries, Dr. Wayal effectively bridges fundamental research and real-world applications. His contributions demonstrate both scientific rigor and translational value, making him a strong contender for recognition such as the BExcellence in Research Award. As he continues to lead and contribute to projects addressing global health challenges, his trajectory indicates not only a promising research career but also the capacity to impact public health through innovation and scientific excellence.
-
Title: Novel bioactive peptides alleviate Western diet-induced MAFLD…
Authors: V. Wayal, S.D. Wang, C.C. Hsieh
Journal: International Immunopharmacology 148
Year: 2025
Citations: 8
-
Title: Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced MAFLD…
Authors: V. Wayal, C.C. Hsieh
Journal: Biomedicine & Pharmacotherapy 168
Year: 2023
Citations: 7
-
Title: ASSESSMENT OF WOUND HEALING ACTIVITY OF POTENT HERBAL EXTRACTS GEL IN ALBINO WISTAR RAT
Authors: V. Wayal, T.N.V.
Journal: Asian Journal of Pharmaceutical and Clinical Research 15(08)
Year: 2022
Citations: 3
-
Title: Design, Development and Evaluation of Silk Based Film Forming Spray for Wound Healing
Authors: V. Wayal, K. Nagasree, B.A. Vishwanath
Journal: Journal of Drug Delivery & Therapeutics 11
Year: 2021
Citations: 3
-
Title: Chicken meat hydrolysate improves acetaminophen-induced liver injury…
Authors: V. Wayal, Z.E. Tsai, Y.H. Lin, Y.H. Lai, S.D. Wang, C.C. Hsieh
Journal: Journal of Agriculture and Food Research 21
Year: 2025
Citations: 1
-
Title: Immunomodulatory effects of type II arabinogalactans from Anoectochilus formosanus…
Authors: Y.L. Huang, W.C. Lin, V. Wayal, C.C. Hsieh
Journal: Carbohydrate Polymer Technologies and Applications
Year: 2025
-
Title: Goat Whey Protein Hydrolysate Mitigates High-Fructose Corn Syrup-Induced Hepatic Steatosis…
Authors: C.H. Shao, V. Wayal, C.C. Hsieh
Journal: Preprints
Year: 2025
-
Title: Type II Arabinogalactan from Anoectochilus Formosanus Dampens Allergic Airway Hyperresponsiveness…
Authors: Y.L. Huang, V. Wayal, W.C. Lin, C.C. Hsieh
Platform: SSRN Preprint
Year: 2025